drugset / Trial / NCT00175305

Prader-Willi Syndrome and Appetite

NCT00175305

Phase 3 Terminated 10 enrolled University of British Columbia
RandomizedParallel-groupDouble-blindTreatment

Summary

Excessive weight gain is a cardinal feature of Prader-Willi syndrome (PWS) for which there is presently no effective treatment. It is caused by increased appetite, decreased perception of satiety and obsessive and compulsive behaviour towards food. Ghrelin is a powerful appetite-stimulating hormone. Patients with PWS have markedly elevated ghrelin levels, suggesting that it may be responsible for the increased food intake. The goal of the study is to determine whether treatment with somatostatin (Sandostatin), a hormone that inhibits ghrelin, is an effective treatment for the prevention and treatment of weight excess in patients with PWS.

Timeline

Start
2004-08
Primary completion
Completion
2007-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Octreotide Peptide Subcutaneous